These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11782050)

  • 21. Practical model-based dose-finding in phase I clinical trials: methods based on toxicity.
    Thall PF; Lee SJ
    Int J Gynecol Cancer; 2003; 13(3):251-61. PubMed ID: 12801254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.
    Iasonos A; Wilton AS; Riedel ER; Seshan VE; Spriggs DR
    Clin Trials; 2008; 5(5):465-77. PubMed ID: 18827039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toxicity equivalence range design (TEQR): a practical Phase I design.
    Blanchard MS; Longmate JA
    Contemp Clin Trials; 2011 Jan; 32(1):114-21. PubMed ID: 20923709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
    Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
    Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.
    Paoletti X; Kramar A
    Stat Med; 2009 Oct; 28(24):3012-28. PubMed ID: 19672839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision-theoretic designs for dose-finding clinical trials with multiple outcomes.
    Fan SK; Wang YG
    Stat Med; 2006 May; 25(10):1699-714. PubMed ID: 16217860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.
    Polley MY
    Stat Med; 2011 Jul; 30(17):2130-43. PubMed ID: 21590790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of sequential dose-finding designs.
    O'Quigley J
    Biometrics; 2005 Sep; 61(3):749-56. PubMed ID: 16135026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving safety of the continual reassessment method via a modified allocation rule.
    Mozgunov P; Jaki T
    Stat Med; 2020 Mar; 39(7):906-922. PubMed ID: 31859399
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Continual reassessment method with regularization in phase I clinical trials.
    Li X; Ivanova A; Tian H; Lim P; Liu K
    J Biopharm Stat; 2020 Nov; 30(6):964-978. PubMed ID: 32926652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small-sample behavior of novel phase I cancer trial designs.
    Oron AP; Hoff PD
    Clin Trials; 2013 Feb; 10(1):63-80. PubMed ID: 23345304
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of two phase I trial designs.
    Korn EL; Midthune D; Chen TT; Rubinstein LV; Christian MC; Simon RM
    Stat Med; 1994 Sep; 13(18):1799-806. PubMed ID: 7997713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A web tool for designing and conducting phase I trials using the continual reassessment method.
    Wages NA; Petroni GR
    BMC Cancer; 2018 Feb; 18(1):133. PubMed ID: 29402249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials.
    Doussau A; Thiébaut R; Paoletti X
    Stat Med; 2013 Dec; 32(30):5430-47. PubMed ID: 24018535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incorporating adverse event relatedness into dose-finding clinical trial designs.
    Darssan D; Thompson MH; Pettitt AN
    Stat Med; 2014 Mar; 33(7):1146-61. PubMed ID: 24122859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The continual reassessment method for dose-finding studies: a tutorial.
    Garrett-Mayer E
    Clin Trials; 2006; 3(1):57-71. PubMed ID: 16539090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
    Normolle D; Lawrence T
    J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding.
    Yan F; Thall PF; Lu KH; Gilbert MR; Yuan Y
    Ann Oncol; 2018 Mar; 29(3):694-699. PubMed ID: 29267863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.